论文部分内容阅读
目的：应用重组干扰素治疗慢性丙型肝炎近期与远期疗效观察研究。方法：3×106IU，ih，1次／2d×3个月为1疗程，接受2－4个疗程干扰素治疗的慢性丙型肝炎患者20例，治疗结束后随访观察1－3年。结果：根据干扰素疗效评价标准，第2个疗程治疗结束时，分别有45，0％（9／20），40．0％（8／20）和15．0％（3／20）的患者表现为完全应答，部分应答和无应答。完全应答者有3例分别在第2疗程结束后的6个月、9个月的间隙期内复发。有6例患者接受3－4个疗程治疗。在2－4个疗程治疗结束后随访1－3年，6例（30．0％）患者表现为持续完全应答，11例（55．0％）患者为部分应答，3例（15．0％）患者无应答。结论：慢性丙型肝炎患者干扰素治疗的早期疗效较好，但完全应答者的复发率较高。
Objective: To observe the short-term and long-term effects of recombinant interferon on chronic hepatitis C patients. METHODS: Twenty patients with chronic hepatitis C were treated with 3 × 106IU, ih, 1 time / 2d × 3 months for one course of treatment and received 2-4 courses of interferon treatment. The patients were followed up for 1-3 years after the end of treatment. Results: According to the Interferon Efficacy Evaluation criteria, 45,0% (9/20), 40.0% (8/20) and 15.0% (3/20) patients at the end of the second course of treatment, respectively The performance of complete response, partial response and no response. Three of the total responders relapsed within the six-month, nine-month gap after the second course of treatment. Six patients received 3-4 courses of treatment. Six to three years after the end of 2-4 courses of treatment, 6 patients (30.0%) showed complete response, 11 (55.0%) had partial response and 3 (15.0% Patients did not respond. Conclusion: The early curative effect of interferon in patients with chronic hepatitis C is better, but the relapse rate of those with complete responders is higher.